Core Viewpoint - The company has approved a performance compensation plan due to the failure of Huanrui Century (Dongyang) Film and Television Media Co., Ltd. to meet performance commitments from 2016 to 2018, necessitating compensation from the responsible parties [1][10]. Summary by Sections 1. Overview of Equity Acquisition - The company completed a significant asset restructuring in 2016 by acquiring 100% of Huanrui Film through a non-public issuance of 391,644,880 shares [1]. 2. Performance Commitment Completion and Asset Impairment Testing - The auditing firm Tianjian issued unqualified audit reports for 2016 and 2017, but a qualified report for 2018, indicating uncertainty regarding the completion of performance commitments due to issues with accounts receivable from the drama "Tianxia Chang'an" [2][3]. 3. Performance Compensation Plan - The total number of shares to be compensated is calculated at 11,556.62 million shares, with a compensation amount of 88,523.71 million yuan, which exceeds the impairment amount of 59,710 million yuan, meaning no asset impairment compensation is required from the original shareholders [7][8][10]. 4. Related Matters and Monitoring Committee Opinion - The monitoring committee has approved the performance compensation plan, confirming that it complies with the agreements and does not harm the interests of the company or its shareholders [9][10]. 5. Independent Financial Advisor's Review - The independent financial advisor confirmed that the original shareholders of Huanrui Film should compensate for the unmet performance commitments, with the compensation amount exceeding the impairment amount [10]. 6. Legal Opinions - The legal opinion states that the compensation methods and quantities comply with legal regulations and contractual agreements, pending approval from the shareholders' meeting [10]. 7. Apology Statement - The company expresses regret for the unmet performance commitments from 2016 to 2018 and commits to enhancing oversight of Huanrui Film to improve operational performance [10].

北京海润天睿律师事务所 关于欢瑞世纪联合股份有限公司 发行股份购买资产暨关联交易 所涉业绩补偿及减值补偿之 法律意见书 致：欢瑞世纪联合股份有限公司 根据欢瑞世纪联合股份有限公司（以下简称"欢瑞世纪"、"公司"）委托，北 京海润天睿律师事务所（以下简称"本所"）指派本所律师就公司 2016 年度发行 股份购买欢瑞世纪（东阳）影视传媒有限公司（原名欢瑞世纪影视传媒股份有限 公司，以下简称"欢瑞影视"）100.00%股权之交易（以下简称"本次交易"）所涉 业绩补偿及减值补偿的有关事宜，出具本法律意见书。 为出具本法律意见书，本所律师根据有关法律、法规、规范性文件的规定和 本所业务规则的要求，本着审慎性及重要性原则对本次交易所涉业绩补偿及减值 补偿相关事宜有关的文件资料和事实进行了核查和验证。 对本法律意见书，本所律师作出如下声明： 供了本所律师认为制作法律意见书所必需的原始书面材料、副本材料和口头证言， 其所提供的文件和材料是真实、准确和完整的，且无隐瞒、虚假和重大遗漏之处。 《中华人民共和国公司法》（以下简称"《公司法》"）、《中华人民共和国证券 法》（以下简称"《证券法》"）等国家现行法律、法规、规范性文件和 ...

Group 1 - The core point of the announcement is the successful completion of performance commitments by Xiamen Luyi Color Masterbatch Co., Ltd., which exceeded the cumulative net profit commitment of 78 million yuan for 2023 and 2024, achieving a total net profit of 78.82 million yuan [1][2] - The Supervisory Board meeting was held on May 21, 2025, with all three supervisors present, and the meeting complied with relevant laws and regulations [1] - The performance commitment report was audited by Lixin Certified Public Accountants, confirming that there were no impairment signs for the assets of Xiamen Luyi Color Masterbatch Co., Ltd. as of December 31, 2024 [2] Group 2 - The Supervisory Board approved the implementation of excess performance rewards and related transactions, deeming them reasonable and not harmful to the interests of the company and its shareholders [2] - The voting results for the proposals were unanimous, with all three votes in favor and no opposition or abstentions [2]

Group 1: Company Overview and Business Segments - The company operates in four main business segments: power distribution equipment, electric vehicle charging stations, photovoltaic and wind power EPC, and biomedicine [2][3][11] - The acquisition of 51% of Rui'en Pharmaceutical is a strategic move to enhance the company's presence in the biomedicine sector [11][12] Group 2: Financial Performance and Goals - In Q1 2025, the company reported a revenue of 60.76 million CNY, a year-on-year increase of 94.47% due to the consolidation of Rui'en Pharmaceutical [11][12] - The company aims to improve its overall financial performance and mitigate delisting risks by enhancing operational management and cost control [3][4][12] Group 3: Risk Management and Compliance - The company is under delisting risk warning due to negative net profit and low revenue, with efforts being made to resolve these issues [4][6][12] - The company plans to apply for the removal of risk warnings once it meets the necessary criteria set by the Shenzhen Stock Exchange [4][6] Group 4: Strategic Initiatives and Future Plans - The company intends to expand its market presence both domestically and internationally, focusing on partnerships and order fulfillment [4][11] - Emphasis will be placed on technological advancements and maintaining customer relationships to enhance operational efficiency and brand reputation [4][11] Group 5: Shareholder Engagement and Market Confidence - The company reassures shareholders that there are no current plans for major asset disposals or reductions in shareholding by major stakeholders [13] - Continuous efforts are being made to improve shareholder value and market confidence through strategic management and operational improvements [13]

Group 1 - The company will hold a shareholders' meeting on May 23, 2024, at 10:00 AM in Beijing, with attendance required from all registered shareholders and representatives [6][9] - The meeting will follow specific rules to ensure order and efficiency, including a combination of on-site and online voting [4][5] - The agenda includes the presentation of various reports and proposals for shareholder approval, including the annual financial report and profit distribution plan [10][11][12] Group 2 - The company reported a net loss of approximately 72.87 million yuan for the year 2024, with retained earnings at -525.30 million yuan, leading to a proposal of no profit distribution for the year [13][16] - The company plans to address its significant losses, which exceed one-third of its paid-in capital, by optimizing cost structures and exploring strategic transformations [16][18] - The company has proposed to purchase directors and officers liability insurance to enhance risk management and protect the interests of investors [19][20] Group 3 - Three independent directors have resigned due to personal reasons, prompting the need for a replacement election at the upcoming shareholders' meeting [21][22] - The board has recommended three candidates for the independent director positions, ensuring compliance with legal requirements [22][23] - The company acknowledges the contributions of the departing independent directors and expresses gratitude for their service [22]

Financial Performance - The company achieved a net profit attributable to shareholders of 61.77 million yuan in 2024, representing an increase of 85.24% compared to the previous year [2] Dividend Distribution - In 2024, the company conducted two cash dividend distributions: 1. In July 2024, a cash dividend of 0.2 yuan per 10 shares was distributed, totaling 11,704,328.44 yuan (including tax) [3] 2. In December 2024, a cash dividend of 0.33 yuan per 10 shares was proposed, totaling 19,312,141.93 yuan (including tax) [3] Business Performance - The gross margin for the specialized chemical business dropped to 1% due to high volatility in silver prices, which constitute a significant portion of product costs [4] - The company is actively participating in the photovoltaic industry to expand market share, even with low margins, to establish a competitive advantage [4] Future Outlook - The performance compensation expected to be paid in 2025 may impact the company's consolidated financial results, with the final amount to be determined through negotiations with relevant parties [4]

《每日经济新闻》记者注意到，世纪华通的股价从去年7月开始波动上涨，从约3元/股（前复权）上涨至目 前约8元/股。 去年，中国证监会对世纪华通作出行政处罚，认定公司2018年至2022年年报商誉有关情况存在虚假记载， 同时还存在虚构业务或提前确认收入的情况，最新的警示函则是这一处罚的延续。 此外，世纪华通对相关财务数据进行了会计差错更正，致使子公司原本已"完成"的业绩承诺未能达成，相 关业绩承诺人需承担超过1亿股的业绩补偿责任。 七名高管遭警示 每经记者｜赵李南 每经编辑｜魏官红 5月12日，ST华通（SZ002602，股价8.01元，市值596.95亿元，即"世纪华通"）公告称，公司相关人员收到 浙江证监局下发的警示函。 此前称完成业绩承诺，现需补偿12.6亿元 2019年，世纪华通向盛趣科技包括曜瞿如、熠趣盛及吉虞梵在内的29名股东以发行股份及支付现金的方式 购买其合计持有的上海盛趣科技（集团）有限公司（原名盛跃网络科技（上海）有限公司，简称"盛趣科 技"）100%股权。 补偿义务人承诺，盛趣科技在业绩承诺期（即2018年度、2019年度和2020年度）内实际实现的合并报表扣 除非经常性损益后归属于母公司股 ...

据正泰电器介绍，正泰电源主要从事光伏逆变器、储能变换器及系统集成研发、生产、销售及服务。 经过上述操作，正泰电源及其控股子公司仍在正泰电器合并报表范围内。"对公司财务状况和经营成果 将产生积极影响。"正泰电器称。 彼时，对于上述交易的意义，正泰电器表示："本次交易有助于整合双方全球销售渠道和资源，通润装 备拥有成熟的海外销售网络和海外销售资源，正泰电源的主要目标市场亦包括欧美等热点市场，在双方 积累的良好市场口碑和较强声誉的基础上，进一步提高公司光伏逆变器和储能产品的品牌影响力。" 同时，正泰电器等交易方也作出了承诺，盎泰电源2023年度、2024年度及2025年度净利润应分别不低于 约0.9亿元、1.1亿元和1.4亿元。已支付约3910万元补偿款 由于盎泰电源在业绩承诺期未完成业绩承诺，正泰电器等需要支付业绩补偿款。 值得注意的是，正泰电器此前通过并购已经是通润装备的控股股东，此举可谓是母子公司之间的"明算 账"。业绩补偿源自两年前的并购事项 2023年2月，正泰电器公告称，其将盎泰电源86.97%股权转让给通润装备，转让价格约7.3亿元。同时， 正泰电器也收购了通润装备。 上述交易完成后，通润装备成为正泰 ...

（原标题：康芝药业年报亏损，控股股东约6亿元业绩补偿承诺何时兑现？） 2025年4月29日，康芝药业股份有限公司（300086.SZ，下称"康芝药业"）发布2024年年报及2025年第一 季度报告。报告显示，2024年度及2025年第一季度，该公司实现的归母净利润分别为-2.16亿 元、-969.17万元，接连出现亏损。 同一天，康芝药业还披露了其控股股东海南宏氏投资有限公司（下称"宏氏投资"）因未按照约定履行业 绩补偿承诺，被中国证券监督管理委员会海南监管局（下称"海南证监局"）采取了责令改正的行政监管 措施。 业绩亏损 高管涨薪 自称为国内领先儿童大健康企业的康芝药业，近年来业绩大起大落，在最近的六年中，有三年出现亏 损；从2021年起，更是出现了盈亏交替的趋势。2021年，康芝药业实现归母净利润0.11亿元，2022年亏 损1.88亿元，2023年盈利0.12亿元，2024年再度由盈转亏。 具体来看，2024年康芝药业实现营业收入4.73亿元，同比下降36.07%；实现归母净利润-2.16亿元，同比 下降1975.20%；实现扣非归母净利润-2.13亿元，同比下降1671.71%。 对于业绩大幅下滑的原 ...

具体详见公司于2020年4月28日在《证券时报》、《上海证券报》及巨潮资讯网 （http://www.cninfo.com.cn）披露的《关于百卓网络2019年度业绩承诺实现情况及业绩补偿方案的公 告》（公告编号：2020-028）。 为维护公司及全体股东的利益，公司依据协议及法律法规规定，向苏州仲裁委员会提起对被申请人（陈 海滨、崔泽鹏、宋禹、陈裕珍、刘美学以及南海金控）的仲裁，请求苏州仲裁委员会裁决被申请人向公 司进行业绩补偿，支付违约金并承担本案的全部仲裁、保全费。 具体详见公司于2020年7月28日在《证券时报》、《上海证券报》及巨潮资讯网 （http://www.cninfo.com.cn）披露的《关于业绩补偿事项提起仲裁的公告》（公告编号：2020-063）。 登录新浪财经APP 搜索【信披】查看更多考评等级 证券代码：002491 证券简称：通鼎互联 公告编号：2025-013 通鼎互联信息股份有限公司关于业绩补偿事项进展的公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假记载、误导性陈述或重大遗 漏。 一、业绩承诺补偿及仲裁情况 2016年6月7日，公司因收购北京百卓网络 ...